Nucleic Acid-based Therapeutics Market By Technology, Applications and End Users - Global Industry Analysis & Forecast to 2027
Published On : October 2018 Pages : 180 Category: Pharmaceuticals Report Code : HC101511
Nucleic Acid-based Therapeutics Market By Technology (Short Inhibitory Sequences, Nucleoside Analogs, Aptamers, Anti-Sense and Anti-Gene, Gene Transfer Therapy, Ribozymes and Nucleoside Analogs), Applications (Multi-genetic disorders and Monogenetic disorders) End Users (Hospitals and Academic & Research Institutes) - Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The Nucleic Acid-based Therapeutics Market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period. Nucleic acid-based therapeutics are utilized to target genes in charge of either the outflow of an ailment causing proteins or to rectify the diminished protein articulation in sicknesses where the nonattendance of the protein adds to a disease. Nucleic corrosive based therapeutics is specific dysfunctions or deficiencies at the atomic level and is focused on treatments. These are utilized particularly to target hereditary disorders and diseases which do not have a certain cure, for example, sickle cell anemia, thalassemia, cystic fibrosis, hemophilia, diabetes and so on. The nucleic acid-based therapeutics are situated in light of precise target distinguishing proof and hereditary profiling and the human quality undertaking has shaped the foundation of these class of medications.
Drivers and Restraints
The fundamental driver for the market for nucleic acid-based therapeutics is the low rates of cure for hereditary maladies with conventional medications. Other market drivers incorporate expanding comprehension of the human hereditary qualities, developing abilities of mapping human tissue molecular targets, rising intensity of programming's to impersonate the human molecular entities, for example, receptors and so forth. In spite of these accomplishments the market for nucleic acid-based medication is developing at a rate not reasonable with their potential. The absence of finish comprehension of human molecular targets and genetics is the most basic requirements.
Regional Insights
Europe stands as the second-largest market for nucleic acid-based therapeutics. The emerging markets are foreseen to keep up their leads owing to the nonexistence of regulatory framework in the emerging and underdeveloped regions of the world such as Asia pacific region and Africa.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- Phylogica
- Benitec Biopharma
- Protagonist Therapeutics
- Caperna
- Oxford BioMedica PLC
- WAVE Life Sciences
- Transgene
- Imugene
- Benitec Biopharma
- Copernicus Therapeutics Inc.
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Nucleic Acid-based Therapeutics Market, By Technology, Estimates and Forecast, 2017-2027($Billion)
o Short Inhibitory Sequences
o Nucleoside Analogs
o Aptamers
o Anti-Sense and Anti-Gene
o Gene Transfer Therapy
o Ribozymes
o Nucleoside Analogs
· Nucleic Acid-based Therapeutics Market, By Application, Estimates and Forecast, 2017-2027($Billion)
o Multi-genetic disorders
o Monogenetic disorders
· Nucleic Acid-based Therapeutics Market, By End User, Estimates and Forecast, 2017-2027($Billion)
o Hospitals
o Academic & Research Institutes
· Nucleic Acid-based Therapeutics Market, By Region, Estimates and Forecast, 2017-2027($Billion)
o North America
§ North America Nucleic Acid-based Therapeutics Market, By Country
o U.S. Nucleic Acid-based Therapeutics Market
o Canada Nucleic Acid-based Therapeutics Market
o Mexico Nucleic Acid-based Therapeutics Market
o Europe
§ Europe Nucleic Acid-based Therapeutics Market, By Country
o Germany Nucleic Acid-based Therapeutics Market
o UK Nucleic Acid-based Therapeutics Market
o France Nucleic Acid-based Therapeutics Market
o Russia Nucleic Acid-based Therapeutics Market
o Italy Nucleic Acid-based Therapeutics Market
o Rest of Europe Nucleic Acid-based Therapeutics Market
o Asia-Pacific
§ Asia-Pacific Nucleic Acid-based Therapeutics Market, By Country
o China Nucleic Acid-based Therapeutics Market
o Japan Nucleic Acid-based Therapeutics Market
o South Korea Nucleic Acid-based Therapeutics Market
o India Nucleic Acid-based Therapeutics Market
o Southeast Asia Nucleic Acid-based Therapeutics Market
o Rest of Asia-Pacific Nucleic Acid-based Therapeutics Market
o South America
§ South America Nucleic Acid-based Therapeutics Market
o Brazil Nucleic Acid-based Therapeutics Market
o Argentina Nucleic Acid-based Therapeutics Market
o Columbia Nucleic Acid-based Therapeutics Market
o Rest of South America Nucleic Acid-based Therapeutics Market
o Middle East and Africa
§ Middle East and Africa Nucleic Acid-based Therapeutics Market
o Saudi Arabia Nucleic Acid-based Therapeutics Market
o UAE Nucleic Acid-based Therapeutics Market
o Egypt Nucleic Acid-based Therapeutics Market
o Nigeria Nucleic Acid-based Therapeutics Market
o South Africa Nucleic Acid-based Therapeutics Market
o Rest of MEA Nucleic Acid-based Therapeutics Market
Table of Contents:
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. SWOT Analysis
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Nucleic Acid-based Therapeutics Market, By Technology
5.1. Introduction
5.2. Global Nucleic Acid-based Therapeutics Revenue and Market Share by Technology (2017-2027)
5.2.1. Global Nucleic Acid-based Therapeutics Revenue and Revenue Share by Technology (2017-2027)
5.3. Short Inhibitory Sequences
5.3.1. Global Short Inhibitory Sequences Revenue and Growth Rate (2017-2027)
5.4. Nucleoside Analogs
5.4.1. Global Nucleoside Analogs Revenue and Growth Rate (2017-2027)
5.5. Aptamers
5.5.1. Global Aptamers Revenue and Growth Rate (2017-2027)
5.6. Anti-Sense and Anti-Gene
5.6.1. Global Anti-Sense and Anti-Gene Revenue and Growth Rate (2017-2027)
5.7. Gene Transfer Therapy
5.7.1. Global Gene Transfer Therapy Revenue and Growth Rate (2017-2027)
5.8. Ribozymes
5.8.1. Global Ribozymes Revenue and Growth Rate (2017-2027)
5.9. Nucleoside Analogs
5.9.1. Global Nucleoside Analogs Revenue and Growth Rate (2017-2027)
6. Nucleic Acid-based Therapeutics Market, By Applications
6.1. Introduction
6.2. Global Nucleic Acid-based Therapeutics Revenue and Market Share by Applications (2017-2027)
6.2.1. Global Nucleic Acid-based Therapeutics Revenue and Revenue Share by Applications (2017-2027)
6.3. Multi-genetic disorders
6.3.1. Global Multi-genetic disorders Revenue and Growth Rate (2017-2027)
6.4. Monogenetic disorders
6.4.1. Global Monogenetic disorders Revenue and Growth Rate (2017-2027)
7. Nucleic Acid-based Therapeutics Market, By End Users
7.1. Introduction
7.2. Global Nucleic Acid-based Therapeutics Revenue and Market Share by End Users (2017-2027)
7.2.1. Global Nucleic Acid-based Therapeutics Revenue and Revenue Share by End Users (2017-2027)
7.3. Hospitals
7.3.1. Global Hospitals Revenue and Growth Rate (2017-2027)
7.4. Academic & Research Institutes
7.4.1. Global Academic & Research Institutes Revenue and Growth Rate (2017-2027)
8. Nucleic Acid-based Therapeutics Market, By Region
8.1. Introduction
8.2. Global Nucleic Acid-based Therapeutics Revenue and Market Share by Regions
8.2.1. Global Nucleic Acid-based Therapeutics Revenue by Regions (2017-2027)
8.3. North America Nucleic Acid-based Therapeutics by Countries
8.3.1. North America Nucleic Acid-based Therapeutics Revenue and Growth Rate (2017-2027)
8.3.2. North America Nucleic Acid-based Therapeutics Revenue (Million USD) by Countries (2017-2027)
8.3.3. United States
8.3.3.1. United States Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.3.4. Canada
8.3.4.1. Canada Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.3.5. Mexico
8.3.5.1. Mexico Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.4. Europe Nucleic Acid-based Therapeutics by Countries
8.4.1. Europe Nucleic Acid-based Therapeutics Revenue and Growth Rate (2017-2027)
8.4.2. Europe Nucleic Acid-based Therapeutics Revenue (Million USD) by Countries (2017-2027)
8.4.3. Germany
8.4.3.1. Germany Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.4. France
8.4.4.1. France Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.5. UK
8.4.5.1. UK Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.6. Russia
8.4.6.1. Russia Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.7. Italy
8.4.7.1. Italy Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.8. Rest of Europe
8.4.8.1. Rest of Europe Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.5. Asia-Pacific Nucleic Acid-based Therapeutics by Countries
8.5.1. Asia-Pacific Nucleic Acid-based Therapeutics Revenue and Growth Rate (2017-2027)
8.5.2. Asia-Pacific Nucleic Acid-based Therapeutics Revenue (Million USD) by Countries (2017-2027)
8.5.3. China
8.5.3.1. China Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.4. Japan
8.5.4.1. Japan Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.5. Korea
8.5.5.1. Korea Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.6. India
8.5.6.1. India Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.7. Southeast Asia
8.5.7.1. Southeast Asia Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.8. Rest of Asia-Pacific
8.5.8.1. Rest of Asia-Pacific Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.6. South America Nucleic Acid-based Therapeutics by Countries
8.6.1. South America Nucleic Acid-based Therapeutics Revenue and Growth Rate (2017-2027)
8.6.2. South America Nucleic Acid-based Therapeutics Revenue (Million USD) by Countries (2017-2027)
8.6.3. Brazil
8.6.3.1. Brazil Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.4. Argentina
8.6.4.1. Argentina Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.5. Columbia
8.6.5.1. Columbia Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.6. Rest of South America
8.6.6.1. Rest of South America Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.7. Middle East and Africa Nucleic Acid-based Therapeutics by Countries
8.7.1. Middle East and Africa Nucleic Acid-based Therapeutics Revenue and Growth Rate (2017-2027)
8.7.2. Middle East and Africa Nucleic Acid-based Therapeutics Revenue (Million USD) by Countries (2017-2027)
8.7.3. Saudi Arabia
8.7.3.1. Saudi Arabia Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.4. United Arab Emirates
8.7.4.1. United Arab Emirates Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.5. Egypt
8.7.5.1. Egypt Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.6. Nigeria
8.7.6.1. Nigeria Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.7. South Africa
8.7.7.1. South Africa Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.8. Turkey
8.7.8.1. Turkey Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.9. Rest of Middle East and Africa
8.7.9.1. Rest of Middle East and Africa Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
9. Company Profiles
9.1. Phylogica
9.1.1. Business Overview
9.1.2. Service Portfolio
9.1.3. Strategic Developments
9.1.4. Revenue and Market Share
9.2. Benitec Biopharma
9.2.1. Business Overview
9.2.2. Service Portfolio
9.2.3. Strategic Developments
9.2.4. Revenue and Market Share
9.3. Protagonist Therapeutics
9.3.1. Business Overview
9.3.2. Service Portfolio
9.3.3. Strategic Developments
9.3.4. Revenue and Market Share
9.4. Caperna
9.4.1. Business Overview
9.4.2. Service Portfolio
9.4.3. Strategic Developments
9.4.4. Revenue and Market Share
9.5. Oxford BioMedica PLC
9.5.1. Business Overview
9.5.2. Service Portfolio
9.5.3. Strategic Developments
9.5.4. Revenue and Market Share
9.6. WAVE Life Sciences
9.6.1. Business Overview
9.6.2. Service Portfolio
9.6.3. Strategic Developments
9.6.4. Revenue and Market Share
9.7. Transgene
9.7.1. Business Overview
9.7.2. Service Portfolio
9.7.3. Strategic Developments
9.7.4. Revenue and Market Share
9.8. Imugene
9.8.1. Business Overview
9.8.2. Service Portfolio
9.8.3. Strategic Developments
9.8.4. Revenue and Market Share
9.9. Benitec Biopharma
9.9.1. Business Overview
9.9.2. Service Portfolio
9.9.3. Strategic Developments
9.9.4. Revenue and Market Share
9.10. Copernicus Therapeutics Inc.
9.10.1. Business Overview
9.10.2. Service Portfolio
9.10.3. Strategic Developments
9.10.4. Revenue and Market Share
10. Global Nucleic Acid-based Therapeutics Market Competition, by Manufacturer
10.1. Global Nucleic Acid-based Therapeutics Revenue and Market Share by Manufacturer (2017-2017)
10.2. Global Nucleic Acid-based Therapeutics Price By Region (2017-2017)
10.3. Top 5 Nucleic Acid-based Therapeutics Manufacturer Market Share
10.4. Market Competition Trend
11. Nucleic Acid-based Therapeutics Market Forecast (2017-2027)
11.1. Global Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
11.2. Nucleic Acid-based Therapeutics Market Forecast by Regions (2017-2027)
11.2.1. North America Nucleic Acid-based Therapeutics Market Forecast (2017-2027)
11.2.1.1. United States Nucleic Acid-based Therapeutics Market Forecast (2017-2027)
11.2.1.2. Canada Nucleic Acid-based Therapeutics Market Forecast (2017-2027)
11.2.1.3. Mexico Nucleic Acid-based Therapeutics Market Forecast (2017-2027)
11.2.2. Europe Nucleic Acid-based Therapeutics Market Forecast (2017-2027)
11.2.2.1. Germany Nucleic Acid-based Therapeutics Market Forecast (2017-2027)
11.2.2.2. France Nucleic Acid-based Therapeutics Market Forecast (2017-2027)
11.2.2.3. UK Nucleic Acid-based Therapeutics Market Forecast (2017-2027)
11.2.2.4. Russia Nucleic Acid-based Therapeutics Market Forecast (2017-2027)
11.2.2.5. Italy Nucleic Acid-based Therapeutics Market Forecast (2017-2027)
11.2.2.6. Rest of Europe Nucleic Acid-based Therapeutics Market Forecast (2017-2027)
11.2.3. Asia-Pacific Nucleic Acid-based Therapeutics Market Forecast (2017-2027)
11.2.3.1. China Nucleic Acid-based Therapeutics Market Forecast (2017-2027)
11.2.3.2. Japan Nucleic Acid-based Therapeutics Market Forecast (2017-2027)
11.2.3.3. Korea Nucleic Acid-based Therapeutics Market Forecast (2017-2027)
11.2.3.4. India Nucleic Acid-based Therapeutics Market Forecast (2017-2027)
11.2.3.5. Southeast Asia Nucleic Acid-based Therapeutics Market Forecast (2017-2027)
11.2.3.6. Rest of Asia-Pacific Nucleic Acid-based Therapeutics Market Forecast (2017-2027)
11.2.4. South America Nucleic Acid-based Therapeutics Market Forecast (2017-2027)
11.2.4.1. Brazil Nucleic Acid-based Therapeutics Market Forecast (2017-2027)
11.2.4.2. Argentina Nucleic Acid-based Therapeutics Market Forecast (2017-2027)
11.2.4.3. Columbia Nucleic Acid-based Therapeutics Market Forecast (2017-2027)
11.2.4.4. Rest of South America Nucleic Acid-based Therapeutics Market Forecast (2017-2027)
11.2.5. Middle East and Africa Nucleic Acid-based Therapeutics Market Forecast (2017-2027)
11.2.5.1. Saudi Arabia Nucleic Acid-based Therapeutics Market Forecast (2017-2027)
11.2.5.2. United Arab Emirates Nucleic Acid-based Therapeutics Market Forecast (2017-2027)
11.2.5.3. Egypt Nucleic Acid-based Therapeutics Market Forecast (2017-2027)
11.2.5.4. Nigeria Nucleic Acid-based Therapeutics Market Forecast (2017-2027)
11.2.5.5. South Africa Nucleic Acid-based Therapeutics Market Forecast (2017-2027)
11.2.5.6. Turkey Nucleic Acid-based Therapeutics Market Forecast (2017-2027)
11.2.5.7. Rest of Middle East and Africa Nucleic Acid-based Therapeutics Market Forecast (2017-2027)
11.3. Nucleic Acid-based Therapeutics Market Forecast by Technology (2017-2027)
11.3.1. Nucleic Acid-based Therapeutics Forecast by Technology (2017-2027)
11.3.2. Nucleic Acid-based Therapeutics Market Share Forecast by Technology (2017-2027)
11.4. Nucleic Acid-based Therapeutics Market Forecast by Applications (2017-2027)
11.4.1. Nucleic Acid-based Therapeutics Forecast by Applications (2017-2027)
11.4.2. Nucleic Acid-based Therapeutics Market Share Forecast by Applications (2017-2027)
11.5. Nucleic Acid-based Therapeutics Market Forecast by End Users (2017-2027)
11.5.1. Nucleic Acid-based Therapeutics Forecast by End Users (2017-2027)
11.5.2. Nucleic Acid-based Therapeutics Market Share Forecast by End Users (2017-2027)
List of Tables
List of Tables and Figures:
Figure United States Nucleic Acid-based Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Nucleic Acid-based Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Nucleic Acid-based Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Nucleic Acid-based Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Nucleic Acid-based Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Nucleic Acid-based Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Nucleic Acid-based Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Nucleic Acid-based Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Nucleic Acid-based Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Nucleic Acid-based Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Nucleic Acid-based Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Nucleic Acid-based Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Nucleic Acid-based Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Nucleic Acid-based Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Nucleic Acid-based Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Nucleic Acid-based Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Nucleic Acid-based Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Nucleic Acid-based Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Nucleic Acid-based Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Nucleic Acid-based Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Nucleic Acid-based Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Nucleic Acid-based Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Nucleic Acid-based Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Nucleic Acid-based Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Nucleic Acid-based Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Nucleic Acid-based Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Nucleic Acid-based Therapeutics Revenue and Revenue Share by Technology (2017-2018)
Figure Global Short Inhibitory Sequences Revenue and Growth Rate (2017-2018)
Figure Global Nucleoside Analogs Revenue and Growth Rate (2017-2018)
Figure Global Aptamers Revenue and Growth Rate (2017-2018)
Figure Global Anti-Sense and Anti-Gene Revenue and Growth Rate (2017-2018)
Figure Global Gene Transfer Therapy Revenue and Growth Rate (2017-2018)
Figure Global Ribozymes Revenue and Growth Rate (2017-2018)
Figure Global Nucleoside Analogs Revenue and Growth Rate (2017-2018)
Table Global Nucleic Acid-based Therapeutics Revenue and Revenue Share by Applications (2017-2018)
Figure Global Multi-genetic disorders Revenue and Growth Rate (2017-2018)
Figure Global Monogenetic disorders Revenue and Growth Rate (2017-2018)
Table Global Nucleic Acid-based Therapeutics Revenue and Revenue Share by End Users (2017-2018)
Figure Global Hospitals Revenue and Growth Rate (2017-2018)
Figure Global Academic & Research Institutes Revenue and Growth Rate (2017-2018)
Table Global Nucleic Acid-based Therapeutics Revenue by Regions (2017-2018)
Figure North America Nucleic Acid-based Therapeutics Growth Rate (2017-2018)
Figure North America Nucleic Acid-based Therapeutics Revenue and Growth Rate (2017-2018)
Figure North America Nucleic Acid-based Therapeutics by Countries (2017-2018)
Figure North America Nucleic Acid-based Therapeutics Revenue (Million USD) by Countries (2017-2018)
Figure United States Nucleic Acid-based Therapeutics Growth Rate (2017-2018)
Figure United States Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Nucleic Acid-based Therapeutics Growth Rate (2017-2018)
Figure Canada Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Nucleic Acid-based Therapeutics Growth Rate (2017-2018)
Figure Mexico Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Nucleic Acid-based Therapeutics Growth Rate (2017-2018)
Figure Europe Nucleic Acid-based Therapeutics Revenue and Growth Rate (2017-2018)
Figure Europe Nucleic Acid-based Therapeutics by Countries (2017-2018)
Figure Europe Nucleic Acid-based Therapeutics Revenue (Million USD) by Countries (2017-2018)
Figure Germany Nucleic Acid-based Therapeutics Growth Rate (2017-2018)
Figure Germany Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Nucleic Acid-based Therapeutics Growth Rate (2017-2018)
Figure France Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Nucleic Acid-based Therapeutics Growth Rate (2017-2018)
Figure UK Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Nucleic Acid-based Therapeutics Growth Rate (2017-2018)
Figure Russia Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Nucleic Acid-based Therapeutics Growth Rate (2017-2018)
Figure Italy Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Nucleic Acid-based Therapeutics Growth Rate (2017-2018)
Figure Rest of Europe Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Nucleic Acid-based Therapeutics Growth Rate (2017-2018)
Figure Asia-Pacific Nucleic Acid-based Therapeutics Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Nucleic Acid-based Therapeutics by Countries (2017-2018)
Figure Asia-Pacific Nucleic Acid-based Therapeutics Revenue (Million USD) by Countries (2017-2018)
Figure China Nucleic Acid-based Therapeutics Growth Rate (2017-2018)
Figure China Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Nucleic Acid-based Therapeutics Growth Rate (2017-2018)
Figure Japan Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Nucleic Acid-based Therapeutics Growth Rate (2017-2018)
Figure Korea Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Nucleic Acid-based Therapeutics Growth Rate (2017-2018)
Figure India Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Nucleic Acid-based Therapeutics Growth Rate (2017-2018)
Figure Southeast Asia Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Nucleic Acid-based Therapeutics Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Nucleic Acid-based Therapeutics Growth Rate (2017-2018)
Figure South America Nucleic Acid-based Therapeutics Revenue and Growth Rate (2017-2018)
Figure South America Nucleic Acid-based Therapeutics by Countries (2017-2018)
Figure South America Nucleic Acid-based Therapeutics Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Nucleic Acid-based Therapeutics Growth Rate (2017-2018)
Figure Brazil Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Nucleic Acid-based Therapeutics Growth Rate (2017-2018)
Figure Argentina Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Nucleic Acid-based Therapeutics Growth Rate (2017-2018)
Figure Columbia Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Nucleic Acid-based Therapeutics Growth Rate (2017-2018)
Figure Rest of South America Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Nucleic Acid-based Therapeutics Growth Rate (2017-2018)
Figure Middle East and Africa Nucleic Acid-based Therapeutics Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Nucleic Acid-based Therapeutics by Countries (2017-2018)
Figure Middle East and Africa Nucleic Acid-based Therapeutics Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Nucleic Acid-based Therapeutics Growth Rate (2017-2018)
Figure Saudi Arabia Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Nucleic Acid-based Therapeutics Growth Rate (2017-2018)
Figure United Arab Emirates Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Nucleic Acid-based Therapeutics Growth Rate (2017-2018)
Figure Egypt Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Nucleic Acid-based Therapeutics Growth Rate (2017-2018)
Figure Nigeria Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Nucleic Acid-based Therapeutics Growth Rate (2017-2018)
Figure South Africa Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Nucleic Acid-based Therapeutics Growth Rate (2017-2018)
Figure Turkey Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Nucleic Acid-based Therapeutics Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Table Phylogica Nucleic Acid-based Therapeutics Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Benitec Biopharma Nucleic Acid-based Therapeutics Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Protagonist Therapeutics Nucleic Acid-based Therapeutics Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Caperna Nucleic Acid-based Therapeutics Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Oxford BioMedica PLC Nucleic Acid-based Therapeutics Price, Revenue, Gross Margin and Market Share (2017-2017)
Table WAVE Life Sciences Nucleic Acid-based Therapeutics Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Transgene Nucleic Acid-based Therapeutics Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Imugene Nucleic Acid-based Therapeutics Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Benitec Biopharma Nucleic Acid-based Therapeutics Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Copernicus Therapeutics Inc. Nucleic Acid-based Therapeutics Price, Revenue, Gross Margin and Market Share (2017-2017)
Figure Global Nucleic Acid-based Therapeutics Market Share by Manufacturer
Figure Global Nucleic Acid-based Therapeutics Revenue and Market Share by Manufacturer
Table Global Nucleic Acid-based Therapeutics Price by Region (2017-2017)
Figure Top 5 Nucleic Acid-based Therapeutics Manufacturer (Revenue) Market Share
Figure Market Competition Trend
Figure Global Nucleic Acid-based Therapeutics Revenue (Millions USD) and Growth Rate (2018-2025)
Table Nucleic Acid-based Therapeutics Market Forecast by Regions (2018-2025)
Figure North America Nucleic Acid-based Therapeutics Market Forecast (2018-2025)
Figure United States Nucleic Acid-based Therapeutics Market Forecast (2018-2025)
Figure Canada Nucleic Acid-based Therapeutics Market Forecast (2018-2025)
Figure Mexico Nucleic Acid-based Therapeutics Market Forecast (2018-2025)
Figure Europe Nucleic Acid-based Therapeutics Market Forecast (2018-2025)
Figure Germany Nucleic Acid-based Therapeutics Market Forecast (2018-2025)
Figure France Nucleic Acid-based Therapeutics Market Forecast (2018-2025)
Figure UK Nucleic Acid-based Therapeutics Market Forecast (2018-2025)
Figure Russia Nucleic Acid-based Therapeutics Market Forecast (2018-2025)
Figure Italy Nucleic Acid-based Therapeutics Market Forecast (2018-2025)
Figure Rest of Europe Nucleic Acid-based Therapeutics Market Forecast (2018-2025)
Figure Asia-Pacific Nucleic Acid-based Therapeutics Market Forecast (2018-2025)
Figure China Nucleic Acid-based Therapeutics Market Forecast (2018-2025)
Figure Japan Nucleic Acid-based Therapeutics Market Forecast (2018-2025)
Figure Korea Nucleic Acid-based Therapeutics Market Forecast (2018-2025)
Figure India Nucleic Acid-based Therapeutics Market Forecast (2018-2025)
Figure Southeast Asia Nucleic Acid-based Therapeutics Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Nucleic Acid-based Therapeutics Market Forecast (2018-2025)
Figure South America Nucleic Acid-based Therapeutics Market Forecast (2018-2025)
Figure Brazil Nucleic Acid-based Therapeutics Market Forecast (2018-2025)
Figure Argentina Nucleic Acid-based Therapeutics Market Forecast (2018-2025)
Figure Columbia Nucleic Acid-based Therapeutics Market Forecast (2018-2025)
Figure Rest of South America Nucleic Acid-based Therapeutics Market Forecast (2018-2025)
Figure Middle East and Africa Nucleic Acid-based Therapeutics Market Forecast (2018-2025)
Figure Saudi Arabia Nucleic Acid-based Therapeutics Market Forecast (2018-2025)
Figure United Arab Emirates Nucleic Acid-based Therapeutics Market Forecast (2018-2025)
Figure Egypt Nucleic Acid-based Therapeutics Market Forecast (2018-2025)
Figure Nigeria Nucleic Acid-based Therapeutics Market Forecast (2018-2025)
Figure South Africa Nucleic Acid-based Therapeutics Market Forecast (2018-2025)
Figure Turkey Nucleic Acid-based Therapeutics Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Nucleic Acid-based Therapeutics Market Forecast (2018-2025)
Figure Global Nucleic Acid-based Therapeutics Forecast by Technology (2018-2025)
Figure Global Nucleic Acid-based Therapeutics Market Share Forecast by Technology (2018-2025)
Figure Global Nucleic Acid-based Therapeutics Forecast by Technology (2018-2025)
Figure Global Nucleic Acid-based Therapeutics Forecast by Applications (2018-2025)
Figure Global Nucleic Acid-based Therapeutics Market Share Forecast by Applications (2018-2025)
Figure Global Nucleic Acid-based Therapeutics Forecast by Applications (2018-2025)
Figure Global Nucleic Acid-based Therapeutics Forecast by End Users (2018-2025)
Figure Global Nucleic Acid-based Therapeutics Market Share Forecast by End Users (2018-2025)
Figure Global Nucleic Acid-based Therapeutics Forecast by End Users (2018-2025)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|